Journal Mobile Options
Table of Contents
Vol. 82, No. 3, 2012
Issue release date: April 2012
Section title: Clinical Study
Oncology 2012;82:131–138
(DOI:10.1159/000336480)

Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02

Ohsumi S. · Shimozuma K. · Ohashi Y. · Takeuchi A. · Suemasu K. · Kuranami M. · Ohno S. · Watanabe T.
aDepartment of Breast Oncology, NHO Shikoku Cancer Center, Matsuyama, bDepartment of Biomedical Sciences, College of Life Science, Ritsumeikan University, Kusatsu, cDepartment of Biostatistics, School of Public Health, University of Tokyo, Tokyo, dArche Clinic, Saitama, eDepartment of Surgery, Kitasato University School of Medicine, Sagamihara, fDepartment of Breast Oncology, NHO Kyushu Cancer Center, Fukuoka, and gHamamatsu Oncology Center, Hamamatsu, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 10/30/2011 10:09:31 AM
Accepted: 1/3/2012
Published online: 3/15/2012

Number of Print Pages: 8
Number of Figures: 6
Number of Tables: 2

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Objective: To elucidate the time course of taxane-induced edema which may affect the patients’ quality of life (QOL). Patients and Methods: Our study included the first 300 Japanese patients assigned to 1 of 4 regimens using docetaxel (DTX) or paclitaxel (PTX) by 1:1:1:1 in a randomized controlled trial to evaluate the efficacy of adjuvant therapies for node-positive breast cancer. Patients’ QOL was prospectively assessed by the Functional Assessment of Cancer Therapy (FACT)-breast and -taxane (FACT-T) subscale. The scores of FACT items regarding edema and body weight were used as indicators of edema. Results: The scores for ‘anasarca’, ‘edema of the hands’ and ‘edema of the legs and feet’ of the FACT-T subscale worsened up to 1–2 months after chemotherapy, and body weights increased remarkably until cycle 8 in patients treated with DTX alone (75 mg/m2, 8 cycles, every 3 weeks). Edema-related symptoms and body weight were relatively stable in the other treatment groups. There were statistically significant differences in the scores of those items and in the changes of body weight both between the DTX-alone group and the other three groups combined, and between the groups using DTX and those using PTX. Conclusion: Many patients receiving DTX for >4 cycles suffered significantly from edema.


  

Author Contacts

Shozo Ohsumi, MD, PhD
Department of Breast Oncology, NHO Shikoku Cancer Center
Kou 160, Minami-umemoto-machi
Matsuyama, Ehime 791-0280 (Japan)
Tel. +81 89 999 1111, E-Mail sosumi@shikoku-cc.go.jp

  

Article Information

The results of this study were presented at the 32nd Annual San Antonio Breast Cancer Symposium (San Antonio, Tex., USA, December 10–14, 2009).

Received: October 30, 2011
Accepted after revision: January 3, 2012
Published online: March 15, 2012
Number of Print Pages : 8
Number of Figures : 6, Number of Tables : 2, Number of References : 31

  

Publication Details

Oncology (International Journal for Cancer Research and Treatment)

Vol. 82, No. 3, Year 2012 (Cover Date: April 2012)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 10/30/2011 10:09:31 AM
Accepted: 1/3/2012
Published online: 3/15/2012

Number of Print Pages: 8
Number of Figures: 6
Number of Tables: 2

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.